查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1425023

小分子創新 CDMO 市場 - 2024 年至 2029 年預測

Small Molecule Innovator CDMO Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 152 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計小分子創新 CDMO 市場在預測期內將以 7.74% 的複合年成長率成長，市場規模從 2022 年的 511.65 億美元增至 2029 年的 862.47 億美元。

隨著世界人口老化，針對老年人需求的醫療服務需求不斷增加。此外，慢性病的盛行率顯著增加，進一步增加了對創新小分子藥物的需求。

此外，各國政府正在增加資源分配，以支持藥物（包括小分子藥物）的開發和製造。這是為了滿足國家日益成長的醫療需求。例如，2023年6月，沙烏地阿拉伯公共投資基金（PIF）成立了醫藥投資公司（Lifera）。 Lifera 定位為商業規模的 CDMO，專注於生產救生和基本藥物。這包括廣泛的醫療解決方案，包括胰島素、疫苗、血漿療法、單株抗體、細胞和基因療法以及創新小分子。這樣營業單位的創建表明了我們對加速藥物成長和應對慢性病擴散和人口老化帶來的挑戰的承諾。

慢性病增加

在全球範圍內，癌症和糖尿病等各種健康狀況的發生率不斷上升，增加了對常用於治療這些疾病的小分子藥物的需求。現有資料顯示該疾病在全球範圍內的盛行率顯著增加。

根據美國癌症協會的數據，在美國，2022 年新增癌症患者人數預計為 983,160 名男性和 934,870 名女性。這些數字強調了癌症作為健康問題的嚴重性，並強調了在醫療保健領域採取積極預防、診斷和治療方法的必要性。

此外，這些統計數據凸顯了製藥領域，特別是小分子藥物領域對解決方案的迫切需求。對這些藥物的需求是因為它們具有降低成本、提供專業知識以及提高藥物開發和製造過程的整體速度和效率的潛力。隨著全球健康形勢的發展，製藥業面臨著滿足對有效治療方法不斷成長的需求的需要，這凸顯了這些服務和醫療解決方案的重要性。

此外，不斷成長的老年人口正在增加對創新醫療服務的需求，特別是在透過合約藥物開發和受託製造廠商（CDMO）進行小分子藥物創新領域。在美國，65歲及以上的人口數將大幅增加，到2020年將達到5,580萬人（佔總人口的16.8%）。這種人口變化顯示了老齡化社會的明顯趨勢。隨著人口持續老化，對滿足老年人獨特需求的醫療解決方案的需求不斷增加。

中國小分子創新藥CDMO市場可望穩定擴大。

該國提供端到端服務的合約開發和受託製造廠商（CDMO）數量顯著增加，臨床試驗活性化的增加預計將支持市場成長。除此之外，中國的高疾病負擔為滿足藥物研發和製造流程不斷成長的需求提供了額外的動力。此外，由於本土專家數量眾多以及臨床試驗機構的監管措施，中國是一個非常適合進行臨床試驗的國家。例如，中國國家藥品監督管理局藥品審查中心致力於以更低的成本提高臨床試驗研究的質量，並支持CDMO服務的發展。

根據世界衛生組織估計，由於預期壽命延長和出生率降低，未來中國人口老化預計將增加數倍。預計到 2040 年，這一數字將從 2019 年的 2.54 億人增加到 4.02 億人。這反映了對藥物研發和藥物開拓的需求不斷成長，推動了小分子創新 CDMO 市場在預測期內的成長。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析

第5章小分子創新 CDMO 市場：依產品

  • 介紹
  • 小分子原料藥
  • 小分子藥物

第6章小分子創新 CDMO 市場：依客戶類型

  • 介紹
  • 臨床前
  • 臨床
  • 商業的

第7章小分子創新 CDMO 市場：依治療領域

  • 介紹
  • 循環系統疾病
  • 腫瘤學
  • 呼吸系統疾病
  • 神經病學
  • 代謝紊亂
  • 感染疾病
  • 其他

第8章小分子創新 CDMO 市場：按地區

  • 介紹
  • 北美洲
    • 依產品
    • 依客戶類型
    • 按治療區域
    • 按國家/地區
  • 南美洲
    • 依產品
    • 依客戶類型
    • 按治療區域
    • 按國家/地區
  • 歐洲
    • 依產品
    • 依客戶類型
    • 按治療區域
    • 按國家/地區
  • 中東/非洲
    • 依產品
    • 依客戶類型
    • 按治療區域
    • 按國家/地區
  • 亞太地區
    • 依產品
    • 依客戶類型
    • 按治療區域
    • 按國家/地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作

第10章 公司簡介

  • CatSci Ltd.
  • Eurofins Scientific
  • Lonza
  • Sai Life Sciences
  • Ardena
  • Recipharm
  • Cambrex
  • Merck Millipore
  • Catalent
  • AGC Pharma Chemicals Europe
簡介目錄
Product Code: KSI061616036

The small molecule innovator CDMO market is projected to grow at a CAGR of 7.74% during the forecast period thereby reaching a market size of US$86.247 billion in 2029 from an initial value of US$51.165 billion in 2022.

The increasing aging population globally is creating demand for healthcare services tailored to the needs of elderly individuals. Additionally, the prevalence of chronic ailments has seen a notable uptick, further fueling the demand for innovative small-molecule drugs.

Moreover, governments are increasingly allocating resources to support the development and manufacturing of pharmaceuticals, including small-molecule drugs. This is in response to the growing healthcare needs of their populations. For instance, the establishment of the pharmaceutical investment company (Lifera) by the Public Investment Fund (PIF) of Saudi Arabia on June 2023. Lifera is positioned as a commercial-scale CDMO with a focus on manufacturing life-saving and essential pharmaceutical products. This includes a diverse range of medical solutions such as insulins, vaccines, plasma therapeutics, monoclonal antibodies, cell and gene therapies, and innovative small molecules . The creation of such entities demonstrates a commitment to fostering the growth of the pharmaceutical and addresses the challenges posed by the surge in chronic diseases and the aging demographic.

Increasing cases of chronic ailments

Globally, the increasing incidence of various health conditions such as cancer and diabetes has led to a heightened demand for small-molecule drugs, which are commonly employed in the treatment of these ailments. The available data indicates a substantial rise in the prevalence of diseases worldwide.

In the United States, as indicated by the American Cancer Society, the estimated number of new cancer cases for the year 2022 stands at 983,160 for males and 934,870 for females. These figures underscore the significant impact of cancer as a prevalent health concern., This highlights the ongoing need for robust efforts in prevention, diagnosis, and treatment within the healthcare landscape.

Further, these statistics underscore the pressing need for pharmaceutical solutions, particularly in the realm of small-molecule drugs. The demand for these medicines is driven by their potential to reduce costs, provide access to specialized expertise, and enhance overall speed and efficiency in drug development and manufacturing processes. As the global health landscape evolves, the pharmaceutical industry faces the need to meet the growing demand for effective treatments, emphasizing the importance of such services and healthcare solutions.

Additionally, the growing elderly demographic is contributing to an increased need for novel healthcare services, specifically in the realm of small molecule innovation through Contract Development and Manufacturing Organizations (CDMOs). In the United States, the population aged 65 and older has undergone significant expansion, totalling 55.8 million individuals or 16.8% of the overall population in 2020. This demographic shift signals a clear trend toward an aging society. As people advance in age, there arises a growing demand for healthcare solutions that is meet the unique needs of the elderly population.

The China small molecule innovator CDMO market is predicted to expand steadily.

The rise in clinical trial activity with a significant increase in contract development & and manufacturing organizations (CDMOs) offering end-to-end services in the country is expected to boost market growth. In addition to this, the high disease burden in China provides further impetus to meet the growing demand for drug development and manufacturing processes. Furthermore, China is a highly preferred country for conducting clinical trials owing to its large pool of local experts and regulatory actions by clinical trial bodies. For instance- NMPA's Center for Drug Evaluation in China takes initiatives to improve the quality of clinical trial studies at low cost, supporting the development of CDMO services.

As per the estimates from WHO, the ageing population in China is expected to grow multifold in upcoming years attributed to longer life expectancy and declining fertility rates. By the year 2040, it is expected to reach 402 million people from 254 million people in 2019. This reflects the increasing demand for drug discovery and development, promoting the growth of the small molecule innovator CDMO market till the forecast period.

Market Key Developments

  • In January 2023, Lonza completed the expansion of its Solid Form Services Facility in Bend, USA. This expanded facility includes dedicated laboratory space designed to support biotech and midsize pharmaceutical companies in their early-stage compound development. It offers comprehensive support for solid form screening, characterization of small molecule active pharmaceutical ingredients (APIs), and early-stage crystallization process development.
  • In September 2022, WuXi STA, a subsidiary of WuXi AppTec, announced the opening of its new sterile lipid nanoparticle formulation facility. The integrated drug product platform CRDMO will offer various services. These include such as pre-formulation, formulation development, solid-state development, and clinical to commercial drug product manufacturing with a wide spectrum of drug delivery technologies.

Segmentation:

By Product

  • Small Molecule API
  • Small Molecule Drug Product

By Customer Type

  • Preclinical
  • Clinical
  • Commercial

By Therapeutic Area

  • Cardiovascular Disease
  • Oncology
  • Respiratory Disorders
  • Neurology
  • Metabolic Disorders
  • Infectious Disease
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • UK
  • France
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. SMALL MOLECULE INNOVATOR CDMO MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. Small Molecule API
  • 5.3. Small Molecule Drug Product

6. SMALL MOLECULE INNOVATOR CDMO MARKET BY CUSTOMER TYPE

  • 6.1. Introduction
  • 6.2. Preclinical
  • 6.3. Clinical
  • 6.4. Commercial

7. SMALL MOLECULE INNOVATOR CDMO MARKET BY THERAPEUTIC AREA

  • 7.1. Introduction
  • 7.2. Cardiovascular Disease
  • 7.3. Oncology
  • 7.4. Respiratory Disorders
  • 7.5. Neurology
  • 7.6. Metabolic Disorders
  • 7.7. Infectious Disease
  • 7.8. Others

8. SMALL MOLECULE INNOVATOR CDMO MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Product
    • 8.2.2. By Customer Type
    • 8.2.3. By Therapeutic Area
    • 8.2.4. By Country
    • 8.2.4.1. United States
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Product
    • 8.3.2. By Customer Type
    • 8.3.3. By Therapeutic Area
    • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Product
    • 8.4.2. By Customer Type
    • 8.4.3. By Therapeutic Area
    • 8.4.4. By Country
    • 8.4.4.1. United Kingdom
    • 8.4.4.2. Germany
    • 8.4.4.3. France
    • 8.4.4.4. Spain
    • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Product
    • 8.5.2. By Customer Type
    • 8.5.3. By Therapeutic Area
    • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Israel
    • 8.5.4.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Product
    • 8.6.2. By Customer Type
    • 8.6.3. By Therapeutic Area
    • 8.6.4. By Country
    • 8.6.4.1. Japan
    • 8.6.4.2. China
    • 8.6.4.3. India
    • 8.6.4.4. South Korea
    • 8.6.4.5. Indonesia
    • 8.6.4.6. Thailand
    • 8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisition, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. CatSci Ltd.
  • 10.2. Eurofins Scientific
  • 10.3. Lonza
  • 10.4. Sai Life Sciences
  • 10.5. Ardena
  • 10.6. Recipharm
  • 10.7. Cambrex
  • 10.8. Merck Millipore
  • 10.9. Catalent
  • 10.10. AGC Pharma Chemicals Europe